Japanese Pharma Profits Drop 38 Percent Due To Foreign Acquisitions, Yen Appreciation
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Dragged by brisk research and development outlays and business acquisition costs, 14 leading Japanese drug makers reported an aggregate income shrinkage of 38 percent in the half-year business period ended Sept. 30, the Japan Pharmaceutical Manufacturers Association reported Nov. 17